| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Depakote (Divalproex) Extended Release For Migraine Prevention NEW YORK, NY -- October 13, 2000 -- The FDA recently approved Depakote ER (divalproex sodium extended-release tablets), a once-a-day formulation for the prevention of migraine headaches in adults. Developed by Abbott Laboratories, Depakote ER is currently available by prescription in the U.S. An estimated 28 million Americans suffer from migraines. Migraines can be debilitating, and can disrupt daily activities and job performance. Statistics show migraine sufferers miss 157 million workdays every year at a cost of as much as 17 billion dollars to the U.S. economy. By taking Depakote ER just once a day, frequent migraine sufferers can prevent migraines before they start, and enjoy their lives again. Related links: Depakote and Abbott Laboratories.
|